Stephen Ray Mitchell - Sep 9, 2021 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
Director
Signature
/s/ Stephen Ray Mitchell
Stock symbol
VNDA
Transactions as of
Sep 9, 2021
Transactions value $
-$90,040
Form type
4
Date filed
9/13/2021, 04:40 PM
Previous filing
Jun 17, 2021
Next filing
Jun 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $63.3K +5.99K +64.95% $10.57 15.2K Sep 9, 2021 Direct
transaction VNDA Common Stock Options Exercise $167K +13.1K +86.34% $12.70 28.3K Sep 9, 2021 Direct
transaction VNDA Common Stock Sale -$320K -19.1K -67.47% $16.74 9.22K Sep 9, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Stock Option (right to buy) Options Exercise $0 -5.99K -100% $0.00* 0 Sep 9, 2021 Common Stock 5.99K $10.57 Direct F3
transaction VNDA Stock Option (right to buy) Options Exercise $0 -13.1K -37.5% $0.00 21.9K Sep 9, 2021 Common Stock 13.1K $12.70 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A portion of the shares was sold to satisfy the exercise price of the stock options.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.53 to $16.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021.
F4 The option vested with respect to 25% of the underlying shares on February 14, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.